Faced with unique immunobiology and marked heterogeneity, treatment strategies for
glioblastoma require therapeutic approaches that diverge from conventional oncological …

Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …

Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …

Highlights•As of July 2018, there were 759 ongoing or projected clinical trials for
glioblastoma.•Drug therapies appear compromised by the need to combat tumour …

Abstract Purpose of Review Targeted therapies are part of biomarker-driven strategies that
exploit actionable molecular targets and have gained traction following survival benefits …

Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …

Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

This is an exciting time in neuro-oncology. Discoveries elucidating the molecular
mechanisms of oncogenesis and the molecular subtypes of glioblastoma multiforme (GBM) …

Background: Glioblastoma multiforme is a malignant intracranial neoplasm that constitutes a
therapeutic challenge because of the associated high morbidity and mortality given the lack …

Introduction: Outcome for glioma (GBM) remains dismal despite advances in therapeutic
interventions including chemotherapy, radiotherapy and surgical resection. The overall …